SEC Form 10-Q filed by Organovo Holdings Inc.
$ONVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
10-Q - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)
S-1 - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)
PRE 14A - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)
4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. ` The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold players in this sector, having an RSI near or below 30. Aslan Pharmaceuticals Ltd (NASDAQ:ASLN) On July 17, ASLAN Pharmaceuticals announced that its Singapore-incorporated, sole o
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California. The presentation entitled "Pharmacokinetics, Safety and Efficacy of the Novel Non-bile Acid FXR Agon
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798. "The promise of FXR314 is strong and I encourage investors to review our newest presentation," said Keith Murphy, Executive Chairman. "As mergers and acquisitions continue to be str
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company's lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and preclinical models. DDW2024 is being held in Washington, D.C. May 18-21, 2024. The poster, titled, "Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel d
SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)
SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)
SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)